(Q46970160)

27 December 2017

title

Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy (English)

1 reference

27 December 2017

1 reference

6

1 reference

27 December 2017

author name string

Kahlert H

1

1 reference

27 December 2017

Suck R

2

1 reference

27 December 2017

Weber B

3

1 reference

27 December 2017

Nandy A

4

1 reference

27 December 2017

Wald M

5

1 reference

27 December 2017

Cromwell O

7

1 reference

27 December 2017

Fiebig H

8

1 reference

27 December 2017

publication date

2 October 2007

1 reference

27 December 2017

International Archives of Allergy and Immunology

published in

1 reference

27 December 2017

volume

145

1 reference

27 December 2017

issue

3

1 reference

27 December 2017

page(s)

193-206

1 reference

27 December 2017

Pollen-related allergy in Europe

cites work

1 reference

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

21 January 2018

1 reference

Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells

21 January 2018

1 reference

IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

21 January 2018

1 reference

Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy.

21 January 2018

1 reference

Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.

21 January 2018

1 reference

Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals

21 January 2018

1 reference

Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis

21 January 2018

1 reference

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

21 January 2018

1 reference

Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy.

21 January 2018

1 reference

Renaissance of the blocking antibody concept in type I allergy

21 January 2018

1 reference

Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.

21 January 2018

1 reference

Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens

21 January 2018

1 reference

Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning.

21 January 2018

1 reference

Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy

21 January 2018

1 reference

Measurement of basophil-activating capacity of grass pollen allergens, allergoids and hypoallergenic recombinant derivatives by flow cytometry using anti-CD203c

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000109288

1 reference

27 December 2017

1 reference

27 December 2017